425: Alumis and ACELYRIN Reaffirm Commitment to All-Stock Merger, Aiming to Create Biopharma Leader

Alumis and ACELYRIN reaffirm their commitment to merge in an all-stock transaction, creating a leading clinical-stage biopharma company focused on immune-mediated diseases.

Summary

• Alumis and ACELYRIN have reaffirmed their commitment to merge in an all-stock transaction.
• The merger aims to create a leading clinical-stage biopharmaceutical company focused on immune-mediated diseases.
• The combined company will have a stronger financial position to support a diverse pipeline with multiple catalysts.
• The pro forma cash position of the combined company is expected to be approximately $737 million as of December 31, 2024.
• This cash position is expected to fund the company's pipeline through multiple key data readouts and operating expenses into 2027.
• The transaction is expected to close in the second quarter of 2025, subject to stockholder approval and customary closing conditions.
• Alumis expects to file the S-4 and begin mailing the proxy statement promptly following completion of the fiscal year 2024 audits and filing of Annual Reports on Form 10-K by each of Alumis and ACELYRIN.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the reaffirmation of the merger, the potential for a stronger financial position, and the diversified pipeline. However, there are inherent risks associated with mergers and clinical-stage companies.

Positives

• The merger creates a company with a differentiated late-stage portfolio of therapies.
• Increased financial flexibility and runway to advance the pipeline and build commercial capabilities are expected.
• The combined company is expected to have a pro forma cash position of approximately $737 million as of December 31, 2024.
• The cash position is expected to fund operations into 2027.
• The merger has the potential for value accretion for the combined company.

Risks

• The proposed transaction may not be completed in a timely manner or at all.
• Required approvals, including stockholder approvals, may not be received.
• The announcement, pendency, or completion of the transaction may affect the ability to retain key personnel and maintain relationships.
• The transaction may divert management's attention from ongoing business operations.
• Legal proceedings related to the transaction could arise.
• The anticipated benefits and synergies of the transaction may not be fully realized or may take longer to realize than expected.
• Integration of the transaction post-closing may not occur as anticipated.
• There are risks relating to the value of Alumis securities to be issued in the proposed transaction.
• Potential delays in initiating, enrolling, or completing preclinical studies and clinical trials exist.

Future Outlook

The combined company expects to advance its pipeline through multiple key data readouts across several clinical trials and to fund operating expenses and capital expenditure requirements into 2027.

Management Comments

• Martin Babler, President, Chief Executive Officer and Chairman of Alumis, said, Alumis and ACELYRIN together will advance exciting breakthroughs for patients and drive long-term value for stockholders through the creation of a leading clinical stage biopharma company in immune-mediated diseases.
• Mina Kim, Chief Executive Officer of ACELYRIN, said, The ACELYRIN Board of Directors is confident that the all-stock transaction with Alumis maximizes long-term value for ACELYRIN stockholders and continues to recommend that stockholders support the planned merger.

Industry Context

The merger reflects a trend in the biopharmaceutical industry to consolidate assets and resources to develop a more robust pipeline and achieve greater financial stability, particularly in the competitive field of immune-mediated diseases.

Comparison to Industry Standards

• It is difficult to compare the results to industry standards as the merger is still in progress.
• Once the merger is complete, the combined company's performance can be compared to other clinical-stage biopharmaceutical companies focused on immune-mediated diseases, such as Bristol Myers Squibb, UCB, and Galapagos NV.
• Key metrics for comparison would include pipeline diversity, clinical trial success rates, cash runway, and market capitalization.

Stakeholder Impact

• Shareholders of both Alumis and ACELYRIN are expected to benefit from the potential value creation of the combined company.
• Patients may benefit from the development of new therapies for immune-mediated diseases.
• Employees of both companies may experience changes as a result of the merger.

Next Steps

• Alumis will file the S-4 registration statement with the SEC.
• Alumis and ACELYRIN will mail the joint proxy statement/prospectus to stockholders.
• Stockholder votes will be held to approve the transaction.
• The transaction is expected to close in the second quarter of 2025, subject to customary closing conditions.

Key Dates